Qiagen N.v. · NYSE:QGEN
Qiagen — Q3 2025 Earnings Presentation
27 slides from Qiagen's earnings presentation, Nov 5, 2025
Slide 1: Q3 2025 results: Delivering results above outlook
Q3 2025 results Delivering results above outlook November 4, 2025
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: Q3 2025: Delivering results above outlook
Q3 2025: Delivering results above outlook Growth Continued solid momentum across the portfolio $533 mn ($525 mn CER) • Core sales +6% CER to $532 mn ahead of outlook for ≥5%; net sales +5% CER Net sales • QIAstat-Dx (+11% CER) and QuantiFERON (+11% CER) lead growth, while Sample technologies +5% CER
Slide 4: Q3 2025: Sales performance and key developments
Q3 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) • +3% CER growth driven by automated consumables +5% Sample • Instrument placements led by QIAcube, QIAsymphony and CER(1) technologies EZ2 systems 533 502 • +11% CER growth suppor
Slide 5: Q3 2025: Portfolio developments
Q3 2025: Portfolio developments Sample technologies: QIAstat-Dx: Genomics / NGS: Advancing automated sample processing Expanding syndromic testing access Advancing NGS solutions Expanding global installed base of High-throughput system expands U.S. Launch of new QIAseq xHYB long read QIAcube Connect
Slide 6: Disciplined capital allocation: Targeted actions to drive growth and enhance shareholder return
Disciplined capital allocation: Targeted actions to drive growth and enhance shareholder return Organic Profitable targeted investments Acquisition of investments into growth pillars and digitization to fuel profitable Parse Biosciences business expansion Expanding Sample technologies into high-grow
Slide 7: Parse Biosciences, the fastest-growing single-cell company, acquired by QIAGEN
Parse Biosciences, the fastest-growing single-cell company, acquired by QIAGEN Key Facts 3,000+ labs globally Number of labs adopting Parse Founded: 2018 3000 HQ in Seattle (U.S.) FTE: ~100 40+ countries Revenue: 2000 ~$22 mn (2024) ~$40 mn (2026 estimate) Acquired data analysis 50 of the top 50 100
Slide 8: The future of high-definition biology is single-cell resolution
The future of high-definition biology is single-cell resolution Single-cell market Opportunity for QIAGEN ~10% CAGR The future standard method for discovery Expanding QIAGEN's Sample tech Shifting to single-cell across all translational portfolio into the scalable fast-growing ~$2.1 bn single-cell m
Slide 9: Q3 2025: Ongoing solid profitability improvements
Q3 2025: Ongoing solid profitability improvements Adj. operating income margin Adj. EPS ahead of Q3 2025 outlook 29.6% 29.6% Adj. +6% to $158 million despite tariffs 30.0% CER operating and currency headwinds income Non- 18% adj. tax rate consistent with operating quarterly estimate income $0.61 Adj
Slide 10: 9M 2025: Continuous high cash flow
9M 2025: Continuous high cash flow Cash flow(1) Debt maturity overview(3) 770 (in $ millions) 20 In $ millions Q3 2025 Q3 2024 Change 624 Operating cash flow 165 182 -10% Purchases of PP&E(2) -46 -43 +5% 124 500 Free cash flow 119 139 -14% Likely repayment in 2025(4) 750 500 164 In $ millions 9M 202
Slide 11: Outlook: Q4 and FY 2025
Outlook: Q4 and FY 2025 As of October 31, 2025 Outlook Q4 2025 FY 2025 Net sales ~+0% CER / +4-5% CER(2) / ~+2% CER core portfolio(1) +5-6% CER core portfolio(1,3) Anticipated currency impact Positive impact of ~+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS ~$0.60 CER ~$2.38 CER (previously
Slide 12: On track to achieve 2025 targets
On track to achieve 2025 targets Delivering solid financial performance Net sales and adjusted EPS exceeded outlook Driving growth through portfolio expansion Building momentum across growth pillars, led by Sample technologies with three new automation launches and the Parse Biosciences acquisition
Slide 13: Welcoming the new Head of Investor Relations
Welcoming the new Head of Investor Relations Daniel Wendorff Appointed Vice President, Head of Investor Relations, effective November 1, 2025 • Will lead QIAGEN's global investor engagement, reporting to Roland Sackers (CFO) • Deep industry experience and capital markets expertise • Joins from Merck
Slide 14: Appendix
QIAGEN Appendix
Slide 15: Q4 and FY 2025: Outlook and assumptions
Q4 and FY 2025: Outlook and assumptions (As of October 31, 2025) Q4 2025 outlook FY 2025 outlook Net sales ~+0% CER / ~+2% CER core portfolio(1) +4-5% CER / +5-6% CER core portfolio(1) Anticipated currency impact(2) Positive impact of ~+1 ppt Positive impact of ~+1 ppt ~$0.60 CER ~$2.38 CER Adjusted
Slide 16: Q3 2025: Consolidated Statements of Income (unaudited)
Q3 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended September 30, 2025 September 30, 2024 Net sales 532,583 501,869 Cost of sales: Cost of sales 187,783 179,817 Acquisition-related intangible amortization 13,541 13,745 Tota
Slide 17: 9M 2025: Consolidated Statements of Income (unaudited)
9M 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Nine months ended Nine months ended September 30, 2025 September 30, 2024 Net sales 1,549,579 1,457,012 Cost of sales: Cost of sales 535,028 777,922 Acquisition-related intangible amortization 40,325 45,030 To
Slide 18: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 YTD 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 170 5% 3% 486 1% 1% Diagnostic solutions(
Slide 19: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 YTD 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 481 7% 6% 1,393
Slide 20: Q3 and 9M 2025: Reconciliation to adjusted results (unaudited)
Q3 and 9M 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Third quarter 2025 Reported results 532.6 331.2 129.2 134.8 (4.7) 3 % 130.1 0.60 Adjustments Business integrat
Slide 21: Q3 and 9M 2025: Footnotes for reconciliation to adjusted results
Q3 and 9M 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025. It also includes costs incurred in connection with streamlining operati
Slide 22: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 532.6 1,549.6 Net sales (CER) 491.2 491.2 524.8 1,541.7 Gross profit 308.7 334.3 331.2 974.2 Gross profit margin 63.8% 62.7% 62.2% 62.
Slide 23: Consolidated Balance Sheets (unaudited)
Consolidated Balance Sheets (unaudited) September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 1,355,594 663,555 Current portion of lon
Slide 24: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Nine months ended September 30, September 30, Nine months ended September 30, September 30, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 317,051 (4
Slide 25: Q3 and 9M 2025: Currency impact
Q3 and 9M 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2025 U.S. dollar 301.8 301.8 57% 0.0 Euro 100.1 94.2 18% -5.9 British pound 22.6 21.8 4% -0.8 Japanese yen 9.7 9.6 2% -0.1 Other currencies 98.4 97.4 19%
Slide 26: Employees as of September 30, 2025
Employees as of September 30, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q3 2025 Q2 2025 Change Production 279 1,106 145 1,530 1,570 -3 % R&D 163 774 55 992 993 0% Sales 563 845 718 2,126 2,104 1% Marketing 73 173 73 319 319 0% Administration 77 455 161 693 67
Slide 27: Your contacts
Your contacts Daniel Wendorff Calendar Vice President E-mail: Head of Investor Relations Sample technologies Deep Dive November 21, 2025 ir@qiagen.com Phone: +49 2103 29 11322 Internet: E-mail: daniel.wendorff@qiagen.com Q4 / FY 2025 results February 2026 corporate.QIAGEN.com Dr. Domenica Martorana